Report Library
All Reports
Datamonitor Healthcare Oncology Disease Analysis: Multiple Myeloma
June 24, 2025
- CD38-based quadruplets incorporating a bortezomib, lenalidomide, and dexamethasone backbone are the standard of care for first-line multiple myeloma (MM) patients
- Four anti-BCMA therapies are approved in the US for MM: CAR-T therapies Abecma and Carvykti for second-line or later and third-line or later disease, respectively, and the bispecific antibodies Tecvayli and Elrexfio for more heavily pretreated disease
- The relapsed/refractory MM treatment setting is becoming increasingly crowded with several approved therapies, including Talvey, a bispecific targeting GPRC5D
- Revlimid and Darzalex currently dominate the market and are used in various combinations across several lines of therapy
| Indications Covered: | Multiple Myeloma (MM) |